Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Fosamprenavir (FPV) with and without ritonavir (RTV) was added to the antiretroviral regimens of human immunodeficiency virus-infected subjects receiving nevirapine (NVP) to evaluate this drug interaction. Significant reductions in plasma amprenavir exposure (25 to 35%) were observed following coadministration of 1,400 mg of FPV twice a day (BID) and 200 mg of NVP BID. A regimen of 700 mg of FPV BID plus 100 mg of RTV BID may be coadministered with NVP without dose adjustment.
DeJesus
Edwin
E
Orlando Immunology Center, Florida, USA.
Piliero
Peter J
PJ
Summers
Kim
K
Wire
Mary Beth
MB
Stein
Daniel S
DS
Masterman
Amanda
A
Lou
Yu
Y
Min
Sherene S
SS
Shelton
Mark J
MJ
D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002219:Carbamates / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D005663:Furans; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000494:pharmacology*; D010755:Organophosphates / Q000494:pharmacology*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D019438:Ritonavir / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D019829:Nevirapine; D019438:Ritonavir; C426859:fosamprenavir